Changes in Body Composition After EPA Supplementation in Head and Neck Patients

Inclusion Criteria:

* \- Age between 18 and 75 years inclusive.
* A performance status 0-1 according to ECOG (Eastern Cooperative Oncology Group) scale at the time of inclusion in the study.
* Expectancy greater than 3 months life.
* Location: oral cavity, oropharynx, larynx,hypopharynx, nasopharynx and sinuses.
* Patients with squamous cell carcinoma of the head and neck classified as locally advanced (Stage III, IVa-IVb).
* Patients with medical conditions to receive neoadjuvant chemotherapy (CT) induction followed by radiotherapy (RDT) normo fraction combined with QT or biological.
* Neutrophil ≥1500 / mm3, platelet count ≥150,000 / mm3 and hemoglobin ≥10g / dL.
* Adequate liver function: total bilirubin ≤ 1 x ULN; aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; Alkaline phosphatase (ALP) ≤ 5 x ULN.
* Serum albumin-adjusted calcium ≤ 1.25 x upper limit of normal (ULN).
* Using an effective contraceptive method for patients of both sexes where the risk of conception and / or pregnancy.
* Signature of written informed consent before any study-specific procedures

Exclusion Criteria:

* \- Metastatic disease (stage IVc).
* Surgery, radiotherapy and / or chemotherapy prior to study disease treatment.
* T3 N0-1 larynx.
* Other stadiums than III or IV without distant metastases and stable disease.
* Another synchronous squamous carcinoma.
* Diagnosis of other malignancy within the past 5 years, except in situ of the cervix and / or adequately treated basal cell carcinoma skin cancer.
* Active infection (infection requiring intravenous antibiotic), including active tuberculosis and HIV diagnosed.
* Uncontrolled hypertension defined as systolic blood pressure ≥180mm Hg and / or diastolic blood pressure≥ 130 mm Hg at rest.
* Pregnancy (absence must be confirmed with β-HCG (Human chorionic gonadotropin) serum test) or lactating.
* Systemic, chronic immune and concomitant treatment, or hormonal treatment of cancer.
* Other concomitant antineoplastic treatment.
* Clinically significant coronary artery or a history of myocardial infarction in the last 12 months or high risk of uncontrolled arrhythmia or uncontrolled heart failure.
* Chronic obstructive pulmonary disease that would have required ≥3 hospitalizations in the last 12 months.
* Uncontrolled active peptic ulcer.
* Presence of a psychological or medical illness that prevented the study by the patient or to grant the signature on the informed consent.
* Abuse of known drugs (with the exception of heavy drinking).
* Allergic reaction known against any component of study treatment.
* Previous treatment with monoclonal antibodies or other inhibitors of signal transduction or treatment directed against the EGFR (epidermal growth factor receptor).
* Any experimental therapy within 30 days prior to study entry.